Entera Bio (ENTX) Total Liabilities (2017 - 2026)

Entera Bio has disclosed Total Liabilities across 9 years of filings, most recently posting $2.4 million for Q1 2026.

• Quarterly Total Liabilities rose 9.95% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 9.95% YoY) and the FY2025 annual result came in at $2.9 million, up 120.76% from the prior year.
• Total Liabilities fell to $2.4 million in Q1 2026, from $2.9 million in the prior quarter.
• Over five years, Total Liabilities peaked at $2.9 million in Q4 2025 and troughed at $1.2 million in Q3 2022.
• A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities tumbled 59.88% — and 2025, when it soared 120.76%.
• Tracing ENTX's Total Liabilities over 5 years: stood at $1.4 million in 2022, then increased by 0.44% to $1.4 million in 2023, then retreated by 5.0% to $1.3 million in 2024, then surged by 120.76% to $2.9 million in 2025, then slipped by 15.56% to $2.4 million in 2026.
• Business Quant data shows ENTX's Total Liabilities at $2.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.2 million in Q3 2025.